Weight loss is safe, but it should not ease the arrhythmia itself.
A clinical trial published in JAMA has quietly complicated one of cardiology's working assumptions: that what causes a condition can, if reversed, undo it. Older adults with persistent atrial fibrillation lost nearly ten percent of their body weight safely over eight months — a genuine achievement — yet their hearts showed no measurable improvement in rhythm, structure, or symptoms. The LOSE-AF trial suggests that in aging bodies where the condition has already taken hold, the damage may have moved beyond the reach of diet alone, asking medicine to look further than the scale for answers.
- A well-designed trial set out to confirm what seemed intuitive — that shedding weight would ease the burden of atrial fibrillation in older patients — and instead returned a null result that unsettles clinical assumptions.
- 118 participants aged 60 to 85 followed structured meal-replacement programs for eight months, achieving nearly 10% weight loss with no serious harm, while controls lost only 3% under standard guidance.
- Despite the meaningful weight difference between groups, every cardiac metric measured — symptom severity, arrhythmia frequency, heart structure on MRI, blood pressure, cholesterol, inflammation — remained statistically unchanged.
- The findings raise an urgent reorientation: for older adults with established persistent AF, weight loss may be necessary for general health but is insufficient as a cardiac therapy, and other interventions must be sought.
- Researchers caution the results may not transfer to younger patients or milder disease stages, leaving the question of weight loss's cardiac benefits open — but narrowed.
For eight months, a clinical trial asked whether older adults with atrial fibrillation could improve their heart health by losing weight. The answer arrived in two parts: yes, they could lose the weight — and no, it did not help their hearts.
The LOSE-AF trial enrolled 118 people between 60 and 85, all overweight and all living with persistent atrial fibrillation, the condition in which the heart's upper chambers quiver rather than beat in rhythm. Half received structured dieting with meal replacements and behavioral counseling; the other half received a single nurse consultation and written guidance. By month eight, the diet group had lost an average of 9.7 percent of their body weight, against just 3.1 percent in controls — a real and safely achieved difference, with no physical decline or serious adverse events.
Yet the cardiac picture was unchanged. Symptom severity, arrhythmia burden, and heart structure measured by MRI showed no meaningful improvement. Blood pressure, cholesterol, and inflammation markers moved no differently between groups. The rate of repeat cardioversion or ablation procedures was identical. By every clinical measure, the intervention had failed its primary purpose.
The finding challenges a foundational assumption: that because excess weight contributes to developing atrial fibrillation, losing it should help reverse the condition. The LOSE-AF researchers suggest that in older adults with persistent AF, the heart's structural changes may have become too entrenched for weight loss alone to undo.
The authors are careful to note that their conclusions apply specifically to this population — older, with established, persistent disease. For younger patients or those earlier in the condition's course, the calculus may differ. But for the people in this trial, the message is precise: weight loss remains worthwhile for overall health, yet it cannot be expected to quiet an arrhythmia that has already reshaped the aging heart.
For eight months, researchers asked a straightforward question: if older adults with atrial fibrillation lost weight, would their hearts behave better? The answer, delivered in a new clinical trial published in JAMA, is more complicated than the premise suggested. Yes, the patients lost weight—nearly 10 percent of their body mass, a meaningful reduction achieved safely and without harm. No, their hearts did not improve.
The LOSE-AF trial enrolled 118 people aged 60 to 85, all carrying extra weight and all living with persistent atrial fibrillation, the condition in which the heart's upper chambers quiver instead of contracting in rhythm. Half the participants received eight months of structured dieting paired with behavioral counseling using meal replacement products and regular check-ins. The other half received standard care: a single nurse consultation and written dietary guidance. The researchers measured everything—symptom severity, arrhythmia burden, cardiac structure, blood pressure, cholesterol, inflammation markers—to see if weight loss would translate into clinical benefit.
The intervention worked as a weight-loss tool. By month eight, the diet group had shed an average of 6.9 kilograms from a baseline of 92.6 kilograms, representing a 9.7 percent reduction. The control group lost only 3.1 percent. The difference was statistically robust and clinically real. Importantly, the weight loss came without serious harm. Physical performance did not decline. No intervention-related adverse events emerged. For anyone worried that aggressive dieting might weaken older bodies, the trial offered reassurance.
But the cardiac metrics told a different story. Patients who lost weight reported no meaningful improvement in atrial fibrillation symptoms. Their arrhythmia burden—the frequency and duration of irregular heartbeats—did not decrease. The heart's structure, measured by cardiac magnetic resonance imaging, showed no evidence of reverse remodeling, the beneficial shrinkage that sometimes occurs when the heart's workload lessens. Blood pressure, cholesterol, and inflammatory markers remained essentially unchanged between groups. The need for repeat cardioversion or catheter ablation procedures did not differ. In the language of clinical trials, the intervention failed its primary endpoint.
This finding challenges a widely held assumption in cardiology. Excess body weight is a well-established risk factor for developing atrial fibrillation in the first place, and weight loss guidelines are robustly supported by evidence from younger populations. But the LOSE-AF trial suggests that in older adults with established, persistent atrial fibrillation, the relationship between weight and symptoms may not be reversible through diet alone. The researchers hypothesize that by the time persistent AF develops in older age, the underlying cardiac remodeling may have become too entrenched for weight loss to undo.
The trial's authors note that their findings do not necessarily apply to younger patients, those with less advanced forms of the condition, or those who achieve greater weight loss over longer periods. But for the population they studied—older adults with persistent AF—the message is clear: weight loss is safe and achievable, but it should not be pursued with the expectation that it will ease symptoms or restore normal heart rhythm. The distinction matters. It means that for these patients, other interventions—medications, procedures, or approaches not yet tested—may be necessary to address the underlying arrhythmia, even as weight management remains important for overall health.
Citas Notables
Weight loss alone may be insufficient to reverse established persistent AF in older adults, although effects may differ in younger patients, those with less advanced AF, or with greater or longer-term weight loss.— LOSE-AF trial authors
La Conversación del Hearth Otra perspectiva de la historia
Why would weight loss help younger people with atrial fibrillation but not older people?
The researchers suggest that persistent AF in older adults may involve structural changes to the heart that have already become permanent. Weight loss might prevent AF from developing, but once it's established and the heart has remodeled, shedding pounds alone can't reverse that damage.
So the patients in the trial—did they feel any different after losing nearly 10 percent of their body weight?
Not in ways the trial could measure. Their symptom severity scores didn't improve. Some may have felt subjectively better, but the standardized measures showed no statistical difference from the control group.
Was there any harm from the diet?
No. That's actually one of the trial's clearest findings. Physical performance didn't decline, there were no serious adverse events, and the weight loss was sustained. The diet was safe, just not effective for the arrhythmia itself.
If weight loss doesn't help, what should older AF patients do?
The trial doesn't answer that. It only shows what weight loss alone cannot do. These patients still need treatment—medications, cardioversion, ablation procedures. Weight management remains important for overall health, but it shouldn't be expected to control the arrhythmia.
Could longer-term weight loss have made a difference?
Possibly. The trial ran for eight months. The researchers acknowledge that greater weight loss over a longer period might produce different results. But they didn't test that, so we don't know.
What's the practical takeaway for a doctor treating an older patient with AF?
Don't promise that weight loss will ease symptoms or restore rhythm. Encourage it for general health reasons, but manage expectations. The arrhythmia will likely require its own targeted treatment.